Home> Industry News > All

Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer

R&DAstraZeneca2017-07-20 09:17Read   0

CHMP positive recommendation is based on Phase III data demonstrating a 20% reduction in risk of disease worsening or death over anastrozole

Plant-Based Diets and Coronary Heart Disease Risk

HealthACC2017-07-20 09:11Read   0

Are plant-based diet indices (PDIs) associated with fewer coronary heart disease (CHD) events?

Involving young people in EMA activities

RegulatorEMA2017-07-20 09:09Read   0

New principles give a voice to patients and consumers under age 18

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating

Commentsthelifesciencesreport2017-07-20 08:52Read   0

News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company.

Surprising genetic variety in childhood brain cancer

TrendDKFZ2017-07-20 08:47Read   0

Medulloblastoma, a malignant tumour of the cerebellum, can occur at any age, but it most commonly affects children. 

Weekly Drug News Round-Up: July 20, 2017

TrendPharmacodia2017-07-20 08:45Read   1

Weekly Drug News Round-Up

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

FrontierDana-Farber2017-07-20 08:42Read   0

A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center -- using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice -- has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.

Combining CAR T cells with existing immunotherapies may overcome resistance in glioblastomas

TrendScience 2017-07-20 08:39Read   0

Genetically modified "hunter" T cells successfully migrated to and penetrated a deadly type of brain tumour known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumour microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.

T-cells lacking HDAC11 enzyme perform more effectively in destroying cancer cells

R&DBlood2017-07-19 09:09Read   1

Researchers at the George Washington University (GW) Cancer Center have discovered a new role for the enzyme, histone deacetylase 11 (HDAC11), in the regulation of T-cell function.

Nipple-sparing mastectomy has low rate of breast cancer recurrence

R&DACS2017-07-19 09:06Read   1

Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-centre study show.

Alcon's return to growth gives Novartis 'options', says CEO

EVENTSpmlive2017-07-19 09:03Read   1

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

Drug pricing spotlight shifts to generics with no rivals

RegulatorEPvantage2017-07-19 09:00Read   1

Renewal of the US FDA’s user fee programme is must-pass legislation every five years, and usually becomes a vehicle for correcting weaknesses in the pharmaceutical sector. With drug prices the focus of industry critics, the 2017 version of this legislation seeks to constrain costs by stimulating generic competition.

First Prev 1 2 3 4 Next Last GO
You may interest
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top